Clinical Trials Browser

Completed × OTHER × palbociclib × Clear all

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Completed

93 enrolled 16 charts

Estrogen Receptor-positive Breast Cancer

NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT04996160 2026-04-17

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

Breast Neoplasms

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Phase 2 Completed

24 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms

NCT03170206 2026-02-12

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Phase 1 Completed

Lung Neoplasms

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

49 enrolled 14 charts

Breast Neoplasms

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT02760030 2025-12-19

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

Breast Neoplasms

NCT01907607 2025-08-24

CYCLIGIST

Phase 2 Completed

29 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02730429 2025-07-31

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Phase 2 Completed

Endometrial Neoplasms

NCT01356628 2025-07-28

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Phase 2 Completed

23 enrolled 12 charts

Gastrointestinal

Liver Neoplasms

NCT03844997 2025-05-31

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Phase 1/2 Completed

35 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03472573 2025-05-15

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1 Completed

Burkitt Lymphoma

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2 Completed

162 enrolled 12 charts

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

Phase 2 Completed

36 enrolled 17 charts

Breast Neoplasms

NCT03774472 2025-02-17

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 11 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT06525675 2024-12-13

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Breast Neoplasms

NCT02491983 2024-12-09

PARSIFAL

Phase 2 Completed

486 enrolled 15 charts

Breast Neoplasms

NCT02530320 2024-11-22

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Phase 2 Completed

34 enrolled 13 charts

Astrocytoma, Oligodendroglioma

NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1 Completed

35 enrolled 19 charts

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

Phase 4 Completed

Breast Neoplasms, Patient Acceptance of Health Care

NCT02389842 2024-09-26

PIPA

Phase 1 Completed

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast Neoplasms

NCT02913430 2024-09-23

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Phase EARLY_PHASE1 Completed

7 enrolled 13 charts

Breast Neoplasms

NCT06607601 2024-09-23

CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

Breast Neoplasms, Neoplasms

NCT03981614 2024-08-22

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Phase 2 Completed

102 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT03530696 2024-08-13

T-DM1

Phase 2 Completed

55 enrolled 19 charts

Breast Neoplasms

NCT02448420 2024-04-18

PATRICIA II

Phase 2 Completed

Breast Neoplasms

NCT06367335 2024-04-16

ETIC

DILI

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

55 enrolled 15 charts

Breast Neoplasms

NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Phase 1 Completed

Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

NCT03936270 2024-02-20

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT04483505 2023-12-28

ROGABREAST

Phase 1 Completed

BreastOther neoplasm

Breast Cancer Metastatic

NCT02101034 2023-12-21

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Phase 1/2 Completed

96 enrolled 17 charts

Squamous Cell Carcinoma of Head and Neck

NCT01864746 2023-12-12

PENELOPE-B

Phase 3 Completed

1,250 enrolled 12 charts

Breast Neoplasms

NCT03054363 2023-11-13

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Phase 1/2 Completed

42 enrolled 16 charts

Breast Neoplasms

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

Glioblastoma

NCT03809988 2023-09-07

PALMIRA

Phase 2 Completed

Breast Neoplasms

NCT03065621 2023-04-19

NeoRHEA

Phase 2 Completed

Breast Cancer Female

NCT03285568 2023-03-31

Patterns of Prescribing and Monitoring of Palbociclib

Breast Neoplasms

NCT03110744 2023-03-27

NCT-PMO-1601

Phase 2 Completed

Chordoma

NCT03447132 2023-03-10

SAFIA

Phase 3 Completed

Breast Neoplasms

NCT03969121 2023-03-10

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT04130152 2022-10-25

PROMETEO II

Phase EARLY_PHASE1 Completed

Breast Neoplasms, Neoplasm, Residual

NCT02448771 2022-10-24

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Phase 1/2 Completed

36 enrolled 28 charts

Breast Neoplasms

NCT02806050 2022-10-12

Palbociclib and FES PET

Phase 2 Completed

Breast Neoplasms